In a survey [5] and other anecdotal reports, parents of children with drug-refractory epilepsy syndromes have reported successful treatment with cannabidiol-enriched marijuana. But little high-quality evidence is available about the efficacy and safety of cannabidiol in patients with Dravet, Lennox-Gastaux, and other pediatric epilepsy syndromes, as shown by a recent Cochrane Collaboration review of four randomized trials totaling 48 patients with epilepsy that found no adverse effects with 200-300 mg daily over short periods but did not report on the efficacy of the drug.
Links
[1] http://www.clinicalneurologynews.com/specialty-focus/epilepsy-spells/single-article-page/orphan-drug-designation-spurs-trials-for-cannabidiol-in-dravet-syndrome/3cdddf60b53b06d4ebe0e707970b5e1c.html?utm_source=MagnetMail&utm_medium=email&utm_term=KMFISCHER%40BELLSOUTH.NET&utm_content=nexus140324_final&utm_campaign=Promising
[2] http://rethinkpot.org/tags/charlottes-web
[3] http://rethinkpot.org/tags/dravet-syndrome
[4] http://rethinkpot.org/tags/orphan-study
[5] http://www.ncbi.nlm.nih.gov/pubmed/24237632